Market Place
Sourcing Support
Lexaria Signs Contract for DehydraTECH GLP-1 Study
14 Nov 2024 //
ACCESSWIRE
Ethics Board Approves Lexaria’s Phase 1b GLP-1 Diabetes Study
13 Nov 2024 //
ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 `Arm`s Race` Developments
07 Nov 2024 //
ACCESSWIRE
Lexaria Reports Positive 12-Week Blood Sugar Results in Study
24 Oct 2024 //
ACCESSWIRE
Lexaria’s GLP-1 Diabetes Study Shows Positive 12-Week Results
22 Oct 2024 //
ACCESSWIRE
Lexaria Announces $5 Million Registered Offering Under Nasdaq Rules
15 Oct 2024 //
ACCESSWIRE
Lexaria`s GLP-1 Human Pilot Study #3 Begins Dosing
09 Oct 2024 //
ACCESSWIRE
Lexaria Updates Current GLP-1 Market
08 Oct 2024 //
ACCESSWIRE
Lexaria Appoints Michael Shankman as Chief Financial Officer
01 Oct 2024 //
ACCESSWIRE
Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
22 Aug 2024 //
BIOSPACE
Positive Results from Lexaria`s Molecular Characterization Study
19 Aug 2024 //
ACCESSWIRE
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
23 May 2024 //
ACCESSWIRE
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
05 Mar 2024 //
ACCESSWIRE
Lexaria`s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
21 Dec 2022 //
PRESS RELEASE
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
10 Nov 2022 //
STREETINSIDER
Lexaria Receives Independent Review Board Approval for its Human Oral Nicotine
01 Nov 2022 //
YAHOO
Lexaria Receives New Patent in Mexico
31 Aug 2022 //
ACCESSWIRE
Lexaria Announces Positive Feedback from Pre-IND Meeting
10 Aug 2022 //
ACCESSWIRE
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
10 Aug 2022 //
PR NEWSWIRE
Lexaria Signs Manufacturing and License Agreements with BevNology
21 Jun 2022 //
THENEWSWIRE
Lexaria Announces R&D Program to Compare First and Only FDA-Approved
01 Nov 2021 //
BIOSPACE
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
05 Oct 2021 //
YAHOO
Lexaria Begins (IND) Enabling Program for DehydraTECH-CBD for Hypertension
08 Sep 2021 //
BIOSPACE
Lexaria shares up 15% premarket on CBD blood pressure study results
07 Sep 2021 //
SEEKINGALPHA
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
27 Jul 2021 //
THENEWSWIRE
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
27 Jul 2021 //
THENEWSWIRE
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
22 Jul 2021 //
BIOSPACE
Lexaria Issues Progress Report on 1st Human Clinical Study of 2021, HYPER-H21-1
07 Jun 2021 //
THENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.